Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANHEPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus PANHEPRIN.
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs PANHEPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and activated factor X (factor Xa), thereby inhibiting blood coagulation.
Initial IV bolus of 80 units/kg, followed by continuous IV infusion at 18 units/kg/hour; subsequent dosing based on aPTT. For DVT/PE: initial bolus of 5,000 units or 80 units/kg, then 1,000-2,000 units/hour continuously.
80 units/kg IV bolus followed by 18 units/kg/hour continuous IV infusion; adjust to maintain aPTT 1.5-2.5 times control.
None Documented
None Documented
30–90 minutes (mean 1.5 h) for therapeutic doses; dose-dependent and saturable elimination: increases with dose (e.g., 100 U/kg: ~56 min; 400 U/kg: ~152 min). At lower doses, half-life may be shorter due to rapid clearance.
Terminal elimination half-life is dose-dependent: at standard IV doses (100 U/kg), mean t½ = 60 min (range 40–90 min); at high doses (400 U/kg), t½ increases to 150 min due to saturable clearance mechanisms. Clinical context: Short t½ necessitates continuous infusion or frequent subcutaneous dosing for sustained anticoagulation.
Renal: minimal intact heparin; primarily hepatic degradation via desulfation and depolymerization into inactive metabolites (uroheparin) excreted renally. Biliary/fecal: negligible (<1%).
Primarily renal excretion of metabolites (desulfated heparin) with a minor biliary/fecal component. Unchanged heparin is not excreted renally; clearance occurs via saturable hepatic metabolism and reticuloendothelial system uptake. Renal excretion accounts for approximately 50% of total clearance at therapeutic doses, while biliary/fecal elimination is <10%.
Category A/B
Category C
Anticoagulant
Anticoagulant